

BLOOD-BRAIN BARRIER TECHNOLOGIES AND GLOBAL MARKETS



PHM075B
July 2014

Kim Lawson
Project Analyst

ISBN: 1-56965-886-2

bcc | Research
Market Forecasting

BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481 USA
866-285-7215 (toll-free within the USA),
or (+1) 781-489-7301
www.bccresearch.com
information@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
STUDY GOALS AND OBJECTIVES	2
REASONS FOR DOING THIS STUDY	2
SCOPE OF REPORT	2
INTENDED AUDIENCE	2
METHODOLOGY	3
INFORMATION SOURCES	3
ANALYST'S CREDENTIALS	3
RELATED BCC RESEARCH REPORTS	3
BCC RESEARCH WEBSITE	3
DISCLAIMER	4
CHAPTER 2 EXECUTIVE SUMMARY	6
<i>SUMMARY TABLE GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS, THROUGH 2019 (\$ MILLIONS)</i>	7
<i>SUMMARY FIGURE GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS, 2012-2019 (\$ MILLIONS)</i>	7
EMERGING BBB TECHNOLOGY MARKET	10
KEY DRIVERS	12
KEY CHALLENGES	13
CHAPTER 3 OVERVIEW	15
MAJOR TRENDS	15
TODAY'S PHARMA MARKET	16
<i>TABLE 1 PHARMACEUTICAL DRUGS MARKET BY GEOGRAPHICAL REGION, THROUGH 2017 (\$ BILLIONS)</i>	17
<i>FIGURE 1 GEOGRAPHIC DISTRIBUTION OF PHARMACEUTICAL DRUGS, 2012 AND 2017 (PERCENT OF GLOBAL SALES)</i>	18
<i>FIGURE 2 EMERGING REGIONS' PHARMACEUTICAL MARKET SHARES COMPARED TO THE U.S. AND EUROPE, 2017 (ESTIMATED \$BILLIONS)</i>	18
<i>FIGURE 3 GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS, BY REGION, 2019* (\$ MILLIONS)</i>	19
<i>FIGURE 4 GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS, BY THERAPEUTIC AREA, 2019* (% OF ALL SALES FROM COMMERCIALIZED DRUGS)</i>	20
<i>FIGURE 5 MOST FREQUENT BBB TARGET AREAS FOR COMPANIES WITH DRUGS IN CLINICAL DEVELOPMENT, 2019* (%)</i>	21
BIOLOGICS	22
<i>TABLE 2 BIOLOGICS IN DEVELOPMENT IN THE U.S. BY THERAPEUTIC CATEGORY, 2013</i>	22
GENERIC SIGNAL NEED FOR INNOVATION	24
NEUROFOCUSING IN THE PHARMA INDUSTRY	24
<i>FIGURE 6 CNS REVENUE DISTRIBUTION BY DISEASE TARGET, 2012 (\$ BILLIONS)</i>	24
<i>TABLE 3 GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS, THROUGH 2019 (NUMBER OF UNITS COMMERCIALIZED)</i>	26
<i>TABLE 4 GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS, BY POSSIBLE CNS INDICATION, 2014 AND 2019 (NUMBER OF UNITS PER INDICATION)</i>	26
<i>TABLE 5 TOP PHARMA COMPANIES BY REVENUE, 2013 (\$ BILLIONS)</i>	27
EMERGING BBB TECHNOLOGY MARKET	28

TOPIC	PAGE NO.
BRIEF HISTORY OF BBB	29
BLOOD BRAIN BARRIER DEFINED	29
BBB COMPONENTS	30
Pericytes	30
Tight Junctions	31
Lipid Barrier	31
Enzymatic Barrier	31
Efflux Pumps	31
BBB ILLUSTRATED	31
<i>FIGURE 7 PARTS OF THE BBB</i>	31
MAIN AREAS OF THE BRAIN	32
<i>FIGURE 8 THE BRAIN: BBB PROTECTS AND BRIDGES IT TO BLOOD VESSELS</i>	32
TREATING DISEASE AND THE BBB	34
MENINGITIS	34
MULTIPLE SCLEROSIS (MS)	34
ENCEPHALITIS	35
ALZHEIMER'S DISEASE (AD)	35
PARKINSON'S DISEASE (PD)	36
BBB TECHNOLOGY CLASSIFICATION	37
MOST COMMON BBB TECHNOLOGY	37
CHALLENGES WITH THE MOST COMMON TECHNOLOGY USED	38
TRANSPORT CONSIDERATIONS	39
Bypassing the BBB	39
BBB TECHNOLOGY DETAILED	39
Chemical Transport Systems	40
Biological Carrier or Transport Systems	40
Physical Force (Energetic) Opening Through Sound Waves (Targeted Ultrasound)	41
Enhancing Biological Transport System Techniques	42
<i>FIGURE 9 METHODS OF CROSSING THE BBB</i>	42
Nanoparticles and Liposomes	43
Nanoparticles	43
<i>TABLE 6 DESIRABLE NANOPARTICLE QUALITIES TO ACT AS BBB TECHNOLOGY</i>	44
Challenges with Nanoparticles	45
Liposomes	45
PATENTS AND INTELLECTUAL PROTECTION	47
<i>TABLE 7 KEY BBB TECHNOLOGY PATENTS</i>	48
ArmaGen's Patent Estate	50
Life After Patenting	53
<i>TABLE 8 SAMPLE OF FINANCIAL DEALS IN CNS THERAPEUTICS IN THE FIVE YEARS ENDING 2013</i>	54
BBB TECHNOLOGY MARKET: PRESENT AND FUTURE	54
<i>TABLE 9 SAMPLE OF FINANCIAL DEALS IN BBB TECHNOLOGY RECEIVED THROUGH PHARMACEUTICAL COMPANY (ESTIMATED, \$ MILLIONS)</i>	55
<i>FIGURE 10 COMPOSITION OF BBB TECHNOLOGY INDUSTRY BY TECHNOLOGY TYPE, 2014* (% OF INDUSTRY)</i>	56
<i>FIGURE 11 COMPOSITION OF BBB TECHNOLOGY BY TECHNOLOGY TYPE IN THE COMMERCIALIZED (THERAPEUTIC DRUG) MARKET, 2019 (% OF MARKET)</i>	56

TOPIC	PAGE NO.
<i>TABLE 10 DRUGS IN DEVELOPMENT USING BBB-PASSAGE TECHNOLOGY, 2014 AND 2019 (NUMBER OF UNITS)</i>	58
<i>FIGURE 12 DRUGS IN DEVELOPMENT USING BBB-PASSAGE TECHNOLOGY, 2014 AND 2019 (NUMBER OF UNITS)</i>	58
<i>TABLE 11 BBB TECHNOLOGY COMPANIES AND RESPECTIVE TECHNOLOGICAL METHOD</i>	59
<i>TABLE 12 BBB TECHNOLOGY COMPANIES AND CORPORATE PARTNERS/LICENSING DEALS OR LARGE INVESTMENT WITH LEAD DISEASE TARGET</i>	61
Genzyme Innovates and Sells Technology to Pharmidex	61
DRUG DEVELOPMENT IN THE CNS	62
Multiple Models Must Be Used	62
BBB Is Its Own Site of Investigation	63
Understanding Interactions and Brain Areas as Distinct	64
<i>TABLE 13 SUCCESS FACTORS IN CNS DRUG DEVELOPMENT USING BBB TECHNOLOGIES</i>	64
What Values Are Best	66
<i>TABLE 14 FREQUENT DRUG DEVELOPMENT CHALLENGES AND THEIR CLINICAL EFFECTS</i>	67
PROMISING RESEARCH	67
PROMISING CNS DRUGS THAT ARE LATER STAGE IN THE DEVELOPMENT PIPELINE FOR POTENTIAL USE WITH BBB TECHNOLOGY	70
Brain Cancer	70
<i>TABLE 15 GLOBAL PIPELINE FOR BRAIN CANCER, THROUGH 2019</i>	71
Anxiety	74
<i>TABLE 16 GLOBAL PIPELINE FOR ANXIETY DISORDER, THROUGH 2019</i>	74
Dementia	75
<i>TABLE 17 GLOBAL PIPELINE FOR ALZHEIMER'S DISEASE, THROUGH 2019</i>	75
Parkinson's disease	77
<i>TABLE 18 GLOBAL PIPELINE FOR PARKINSON'S DISEASE, THROUGH 2019</i>	77
Depression	78
<i>TABLE 19 GLOBAL PIPELINE FOR DEPRESSION, THROUGH 2019</i>	78
Personality/Psychiatric Disorders (Schizophrenia/bipolar)	79
<i>TABLE 20 GLOBAL PIPELINE FOR SCHIZOPHRENIA, THROUGH 2019</i>	80
Spinal Cord Injury	80
<i>TABLE 21 GLOBAL PIPELINE FOR SPINAL CORD INJURY, THROUGH 2019</i>	81
Addiction Disorders	81
<i>TABLE 22 GLOBAL PIPELINE FOR ADDICTION DISORDERS, THROUGH 2019</i>	81
Attention Deficit Hyperactivity Disorder (ADHD)	82
<i>TABLE 23 GLOBAL PIPELINE FOR ATTENTION DEFICIT HYPERACTIVITY DISORDER, THROUGH 2019</i>	82
Sleep Disorders	83
<i>TABLE 24 GLOBAL PIPELINE FOR SLEEP DISORDERS, THROUGH 2019</i>	83
CHAPTER 4 COMPANY PROFILES	86
ABLYNX	86
ADENIOS	87
ANGIOCHEM	87
ARMAGEN TECHNOLOGIES	89
BIOASIS TECHNOLOGIES	90

TOPIC	PAGE NO.
BRISTOL-MYERS SQUIBB	91
CAPSULATION PHARMA	92
DAINIPPON SUMITOMO PHARMA	93
ELI LILLY AND COMPANY	93
EUTHYMICS BIOSCIENCE	94
FABRE-KRAMER PHARMACEUTICALS	95
FLOCEL	95
FORUM PHARMACEUTICALS	96
GENZYME	97
INSIGHTEC	97
INTERNATIONAL BRAIN BARRIERS SOCIETY (IBBS)	98
ISIS INNOVATION	98
JANSSEN PHARMACEUTICA	99
H LUNDBECK	100
MEDGENESIS THERAPEUTIX (BIOVAIL LAB)	101
MEDIMMUNE	101
MEDINVENT	102
NANOMERICS	102
NEUROVIVE PHARMACEUTICAL	103
NEUREN PHARMACEUTICALS	103
NSGENE	104
OPTINOSE	106
OSSIANIX	106
OTSUKA AMERICA PHARMACEUTICAL	107
PROTHENA CORP	107
PROTHERAGEN	108
PFIZER	108
PHARMACO-CELL	109
PHARMIDEX	109
RAPTOR PHARMACEUTICAL	111
ROCHE	112
ROYALTY PHARMA	112
SHIRE	113
SANERON CCEL THERAPEUTICS	113
SOLVO BIOTECHNOLOGY	114
SOVICELL	115
TEVA PHARMACEUTICAL INDUSTRIES	115
TO-BBB TECHNOLOGIES	116
TTY BIOPHARM	117
UCB	118
VECT-HORUS	118
XENOPORT	119
XIGEN	120

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS, THROUGH 2019 (\$ MILLIONS)	7
TABLE 1 PHARMACEUTICAL DRUGS MARKET BY GEOGRAPHICAL REGION, THROUGH 2017 (\$ BILLIONS)	17
TABLE 2 BIOLOGICS IN DEVELOPMENT IN THE U.S. BY THERAPEUTIC CATEGORY, 2013	22
TABLE 3 GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS, THROUGH 2019 (NUMBER OF UNITS COMMERCIALIZED)	26
TABLE 4 GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS, BY POSSIBLE CNS INDICATION, 2014 AND 2019 (NUMBER OF UNITS PER INDICATION)	26
TABLE 5 TOP PHARMA COMPANIES BY REVENUE, 2013 (\$ BILLIONS)	27
TABLE 6 DESIRABLE NANOPARTICLE QUALITIES TO ACT AS BBB TECHNOLOGY	44
TABLE 7 KEY BBB TECHNOLOGY PATENTS	48
TABLE 8 SAMPLE OF FINANCIAL DEALS IN CNS THERAPEUTICS IN THE FIVE YEARS ENDING 2013	54
TABLE 9 SAMPLE OF FINANCIAL DEALS IN BBB TECHNOLOGY RECEIVED THROUGH PHARMACEUTICAL COMPANY (ESTIMATED, \$ MILLIONS)	55
TABLE 10 DRUGS IN DEVELOPMENT USING BBB-PASSAGE TECHNOLOGY, 2014 AND 2019 (NUMBER OF UNITS)	58
TABLE 11 BBB TECHNOLOGY COMPANIES AND RESPECTIVE TECHNOLOGICAL METHOD	59
TABLE 12 BBB TECHNOLOGY COMPANIES AND CORPORATE PARTNERS/LICENSING DEALS OR LARGE INVESTMENT WITH LEAD DISEASE TARGET	61
TABLE 13 SUCCESS FACTORS IN CNS DRUG DEVELOPMENT USING BBB TECHNOLOGIES	64
TABLE 14 FREQUENT DRUG DEVELOPMENT CHALLENGES AND THEIR CLINICAL EFFECTS	67
TABLE 15 GLOBAL PIPELINE FOR BRAIN CANCER, THROUGH 2019	71
TABLE 16 GLOBAL PIPELINE FOR ANXIETY DISORDER, THROUGH 2019	74
TABLE 17 GLOBAL PIPELINE FOR ALZHEIMER'S DISEASE, THROUGH 2019	75
TABLE 18 GLOBAL PIPELINE FOR PARKINSON'S DISEASE, THROUGH 2019	77
TABLE 19 GLOBAL PIPELINE FOR DEPRESSION, THROUGH 2019	78
TABLE 20 GLOBAL PIPELINE FOR SCHIZOPHRENIA, THROUGH 2019	80
TABLE 21 GLOBAL PIPELINE FOR SPINAL CORD INJURY, THROUGH 2019	81
TABLE 22 GLOBAL PIPELINE FOR ADDICTION DISORDERS, THROUGH 2019	81
TABLE 23 GLOBAL PIPELINE FOR ATTENTION DEFICIT HYPERACTIVITY DISORDER, THROUGH 2019	82
TABLE 24 GLOBAL PIPELINE FOR SLEEP DISORDERS, THROUGH 2019	83

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS, 2012-2019 (\$ MILLIONS)	7
FIGURE 1 GEOGRAPHIC DISTRIBUTION OF PHARMACEUTICAL DRUGS, 2012 AND 2017 (PERCENT OF GLOBAL SALES)	18
FIGURE 2 EMERGING REGIONS' PHARMACEUTICAL MARKET SHARES COMPARED TO THE U.S. AND EUROPE, 2017 (ESTIMATED \$BILLIONS)	18
FIGURE 3 GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS, BY REGION, 2019* (\$ MILLIONS)	19
FIGURE 4 GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS, BY THERAPEUTIC AREA, 2019* (% OF ALL SALES FROM COMMERCIALIZED DRUGS)	20
FIGURE 5 MOST FREQUENT BBB TARGET AREAS FOR COMPANIES WITH DRUGS IN CLINICAL DEVELOPMENT, 2019* (%)	21
FIGURE 6 CNS REVENUE DISTRIBUTION BY DISEASE TARGET, 2012 (\$ BILLIONS)	24
FIGURE 7 PARTS OF THE BBB	31
FIGURE 8 THE BRAIN: BBB PROTECTS AND BRIDGES IT TO BLOOD VESSELS	32
FIGURE 9 METHODS OF CROSSING THE BBB	42
FIGURE 10 COMPOSITION OF BBB TECHNOLOGY INDUSTRY BY TECHNOLOGY TYPE, 2014* (% OF INDUSTRY)	56
FIGURE 11 COMPOSITION OF BBB TECHNOLOGY BY TECHNOLOGY TYPE IN THE COMMERCIALIZED (THERAPEUTIC DRUG) MARKET, 2019 (% OF MARKET)	56
FIGURE 12 DRUGS IN DEVELOPMENT USING BBB-PASSAGE TECHNOLOGY, 2014 AND 2019 (NUMBER OF UNITS)	58